Novel therapy based on camelid nanobodies

Ther Deliv. 2013 Oct;4(10):1321-36. doi: 10.4155/tde.13.87.

Abstract

Nanobodies (Nbs) are small antibody fragments derived from camelid heavy chain antibodies through recombinant gene technology. Their exceptional physicochemical properties, possibility of humanization and unique antigen recognition properties make them excellent candidates for targeted delivery of biologically active components. Several different therapeutic approaches based on the novel camelid Nbs have been developed to treat a wide range of diseases ranging from immune, bone, blood and neurological disorders; infectious diseases and cancer. This review provides a comprehensive overview of the current state of the use of camelid-derived Nbs as novel therapeutic agents against multiple diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibody Specificity
  • Camelids, New World / immunology*
  • Camelus / immunology*
  • Chemistry, Pharmaceutical
  • Drug Carriers
  • Humans
  • Immunotherapy / methods*
  • Immunotoxins / chemistry
  • Immunotoxins / immunology
  • Immunotoxins / therapeutic use*
  • Nanomedicine / methods*
  • Protein Conformation
  • Single-Domain Antibodies / chemistry
  • Single-Domain Antibodies / immunology
  • Single-Domain Antibodies / therapeutic use*
  • Structure-Activity Relationship

Substances

  • Drug Carriers
  • Immunotoxins
  • Single-Domain Antibodies